Hyper-IgE syndrome is a primary immunodeficiency marked by abnormalities in the coordination of cell-cell signaling with the potential to affect T H17 cell, B cell, and neutrophil responses. Clinical manifestations include recurrent skin and lung infections, serum IgE elevation, connective tissue repair and development alterations, and the propensity for vascular abnormalities and tumor development. Signal transducer and activator of transcription 3 (STAT3) signaling, dedicator of cytokinesis 8 (DOCK8) signaling, and tyrosine kinase 2 (TYK2) signaling alterations have been implicated in 3 forms of hyper-IgE syndrome. © 2012 by World Allergy Organization.
CITATION STYLE
Rael, E. L., Marshall, R. T., & McClain, J. J. (2012). The hyper-ige syndromes: Lessons in nature, from bench to bedside. World Allergy Organization Journal. BioMed Central Ltd. https://doi.org/10.1097/WOX.0b013e31825a73b2
Mendeley helps you to discover research relevant for your work.